Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST

Article Gastroenterology & Hepatology

Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial

Silvio Danese et al.

Summary: In patients with moderate-to-severe active Crohn's disease, a treat-to-target strategy with early endoscopy, biomarker monitoring, and dose intensification did not result in significantly better endoscopic outcomes at week 48 compared to a clinically driven maintenance strategy.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis

Nghia H. Nguyen et al.

Summary: Proactive therapeutic drug monitoring did not offer clinical benefit in patients with inflammatory bowel disease treated with TNF alpha antagonists. The certainty of evidence is low.

GASTROENTEROLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies

William J. Sandborn et al.

Summary: The study indicates that ustekinumab exhibits similar safety and efficacy profiles in patients with ulcerative colitis as it does in those with Crohn's disease, with no significant differences compared to placebo.

INFLAMMATORY BOWEL DISEASES (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

Dan Turner et al.

Summary: STRIDE-II presents treatment targets for both adult and pediatric IBD, including long-term and short-term goals. These targets cover aspects such as clinical response, endoscopic healing, quality of life, and growth, providing guidance for improving patient outcomes.

GASTROENTEROLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology